PhaseRx Inc
PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder program… Read more
PhaseRx Inc (PZRXQ) - Total Liabilities
Latest total liabilities as of September 2017: $6.34 Million USD
Based on the latest financial reports, PhaseRx Inc (PZRXQ) has total liabilities worth $6.34 Million USD as of September 2017.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
PhaseRx Inc - Total Liabilities Trend (2014–2016)
This chart illustrates how PhaseRx Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
PhaseRx Inc Competitors by Total Liabilities
The table below lists competitors of PhaseRx Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alveen
PA:MLALV
|
France | €792.00K |
|
WATER RES GRP
BE:WXV
|
Germany | €3.50 Million |
|
Tristar Wellness
PINK:TWSI
|
USA | $17.34 Million |
|
ACTIVEX
BE:A4T
|
Germany | €2.43 Million |
|
Arete Industries Inc
PINK:ARET
|
USA | $3.48 Million |
|
Imagin Medical Inc
PINK:IMEXF
|
USA | $13.08 Million |
|
Finseta Plc
LSE:FIN
|
UK | GBX4.91 Million |
Liability Composition Analysis (2014–2016)
This chart breaks down PhaseRx Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -21.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PhaseRx Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PhaseRx Inc (2014–2016)
The table below shows the annual total liabilities of PhaseRx Inc from 2014 to 2016.
| Year | Total Liabilities | Change |
|---|---|---|
| 2016-12-31 | $7.15 Million | -86.46% |
| 2015-12-31 | $52.80 Million | +19.48% |
| 2014-12-31 | $44.20 Million | -- |